We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
from SECTION 4 - WHAT QUESTIONS ARE BEING ASKED BY CURRENT CLINICAL TRIALS?
Published online by Cambridge University Press: 05 February 2014
Introduction
The introduction in 1987 of a national cervical screening programme in the UK led, in little more than a decade, to a halving in the incidence of cervical cancer from 16 per 100000 to 8 per 100 000 by the year 2000. Despite similar success in other developed countries, cervical cancer remains a major international problem. It is the second most common female cancer worldwide, with almost 500 000 new cases diagnosed annually and 250 000 deaths each year.
The standard ofcare for early-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage IA, IB1) remains surgery. For more advanced disease chemoradiotherapy is preferred. Despite recent improvements in survival, due in the main to the introduction of chemoradiotherapy, the overall pelvic relapse rate remains significant, with the disease recurring in the pelvis in over a quarter of women. This highlights the need for continued effort to improve outcome in this disease. Five year survival rates are around 90%, 75%, 50% and 20% for FIGO stages I, IB2/II, III and IV, respectively.
The challenges in treating cervical cancer are centred on improvements in survival and local control and minimising treatment-related morbidity. This chapter focuses on the evidence for current practice and highlights future research issues.
The role of surgery
Surgery remains the treatment ofchoice in early-stage disease. The most widely quoted data to support this come from an article published in 1997.
To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
